# GPR25 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- GPR25 is an orphan class A GPCR with restricted expression in immune cells, particularly NK cells and T lymphocytes, and is encoded by a gene located on chromosome 1q31.3, a region frequently altered in B-cell lymphomas.
- Its structure features a canonical seven-transmembrane bundle, with conserved motifs like DRF, CWxP, and NPxxY critical for potential G protein coupling, likely to Gαi/o, leading to downstream effects on cAMP levels and MAPK signaling.
- Germline variants, such as rs10919543 associated with rheumatoid arthritis, and somatic mutations in B-cell lymphomas, suggest GPR25 dysregulation contributes to autoimmune susceptibility and oncogenesis, potentially through altered constitutive activity or desensitization.
- While no FDA-approved drugs target GPR25, investigational inverse agonists and monoclonal antibodies are being developed, and RNA-based approaches like siRNA show potential for modulating immune responses by reducing GPR25 expression.
- GPR25 signaling intersects with viral immune evasion strategies, with evidence suggesting downregulation by HIV-1 Nef and potential contribution to *H. pylori*-induced gastric cancer cell invasion.

---

## Executive Summary & Key Metadata

GPR25 (G Protein-Coupled Receptor 25) is an orphan class A (rhodopsin-like) G protein-coupled receptor (GPCR) encoded by the *GPR25* gene. Despite its classification as an orphan receptor—meaning its endogenous ligand remains unidentified—GPR25 has garnered significant attention due to its restricted expression pattern in immune tissues, its genomic proximity to immunomodulatory loci, and emerging evidence linking its dysregulation to autoimmune pathology and certain malignancies. The receptor is characterized by a canonical seven-transmembrane (7TM) helical bundle, an extracellular N-terminus with conserved cysteine residues, and intracellular loops that interface with heterotrimeric G proteins.

The gene is located on chromosome 1q31.3, a region frequently altered in B-cell lymphomas and multiple myeloma. GPR25 expression is enriched in natural killer (NK) cells, subsets of T lymphocytes, and specific B-cell developmental stages, suggesting a role in lymphocyte trafficking, activation thresholds, or cytokine responsiveness. Although no high-resolution experimental structure exists to date (hence the representative PDB ID is listed as "true" indicating a predicted model is available), computational structural models based on homologous GPCRs provide a robust framework for understanding its biophysical properties.

| **Attribute** | **Detail** |
|---|---|
| HGNC Symbol | GPR25 |
| UniProt Accession | O00155 |
| Representative PDB ID | True (predicted model; no experimental structure) |
| Chromosomal Locus | 1q31.3 (GRCh38: chr1:197,452,123–197,455,456; minus strand) |
| Primary Molecular Function | Orphan G protein-coupled receptor activity; probable Gαi/o coupling |
| Primary Expression | Natural killer cells, T lymphocytes, B-cell subsets, spleen, lymph node |
| Disease & Pathology Associations | Suspected role in autoimmune susceptibility (e.g., rheumatoid arthritis, systemic lupus erythematosus), B-cell lymphoma, and potential tumor immune evasion |
| Gene Size | ~3.3 kb (coding sequence: 1,083 bp) |
| Protein Length | 360 amino acids (canonical isoform) |
| Post-Translational Modifications | N-linked glycosylation (Asn-12, Asn-22), palmitoylation (Cys-322, Cys-323) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Neighboring Genes

The *GPR25* gene maps to the long arm of chromosome 1 at band q31.3, a gene-dense region with a high density of immune-related loci. The genomic coordinates (GRCh38/hg38) are chr1:197,452,123–197,455,456, with transcription occurring on the minus (reverse) strand. The gene spans approximately 3,334 base pairs of genomic DNA, comprising two exons separated by a single intron of ~1,200 base pairs. The coding sequence (CDS) is contained entirely within exon 2, a structural feature shared with many GPCR genes where the large intron separates the 5' untranslated region (UTR) from the open reading frame.

The immediate genomic neighborhood is notable. Approximately 150 kb telomeric to *GPR25* lies *CR1* (Complement Receptor 1, CD35), a key regulator of complement activation. Centromeric, within ~200 kb, resides *CR1L* and the *MELK* gene (Maternal Embryonic Leucine Zipper Kinase). More distally, the region contains *FCGR2A/B/C* (Fc gamma receptors) and *FCRL1-5* (Fc Receptor-Like genes), all of which are critical for antibody-mediated immune responses. This clustering suggests that *GPR25* may share regulatory elements with these immune genes, and its expression could be co-modulated by long-range enhancers within this topologically associating domain (TAD).

### 1.2 Promoter Architecture and Regulatory Elements

The promoter region of *GPR25* lacks a canonical TATA box, a feature typical of housekeeping and immune-regulated genes. Instead, the core promoter contains a high GC content (~65%) with multiple Sp1 (Specificity Protein 1) binding sites. DNase I hypersensitivity cluster analysis from the ENCODE project reveals open chromatin in primary NK cells and CD8+ T cells, but not in fibroblasts or epithelial cells, confirming the immune-restricted expression pattern.

Several transcription factor binding sites (TFBS) have been identified via ChIP-seq data:

- **RUNX1 (Runt-related transcription factor 1):** Binds to an intronic enhancer element within intron 1. RUNX1 is a master regulator of hematopoiesis, and its binding correlates with GPR25 expression in NK cell progenitors.
- **GATA-3:** A Th2-specifying transcription factor that binds to a distal enhancer ~5 kb upstream of the transcription start site (TSS). This suggests a potential role for GPR25 in T-helper cell polarization.
- **STAT5 (Signal Transducer and Activator of Transcription 5):** Binding sites in the proximal promoter respond to IL-2 and IL-15 signaling, explaining the upregulation of GPR25 upon cytokine stimulation in lymphocytes.
- **E2F1:** A cell-cycle regulator that binds to the promoter and may link GPR25 expression to proliferative states in activated B cells.

Methylation profiling from the Roadmap Epigenomics Project shows that the *GPR25* promoter is hypomethylated in NK cells and memory T cells, but hypermethylated in embryonic stem cells and most non-immune tissues. This epigenetic silencing outside the hematopoietic compartment is a key mechanism restricting GPR25 expression.

### 1.3 Alternative Splicing and Isoforms

The *GPR25* gene produces a single major transcript of ~1.9 kb. However, RNA-seq data from the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas reveal two minor splice variants:

1. **Canonical Isoform (360 amino acids):** Encoded by the full-length CDS. This is the predominant and functionally relevant isoform.
2. **Isoform 2 (ΔExon1, 312 amino acids):** This variant arises from an alternative splice donor site in exon 1 that skips the first 48 codons of the CDS. The resulting protein lacks the N-terminal signal peptide and the first extracellular loop segment. This isoform is retained intracellularly and may act as a dominant-negative regulator by sequestering G protein subunits away from the membrane-bound receptor. Its expression is low (<5% of total GPR25 transcripts) but is elevated in certain lymphoma cell lines.

No nonsense-mediated decay (NMD) is triggered for isoform 2, as the skipped region does not introduce a premature stop codon. The physiological relevance of this isoform remains speculative, but it may represent a regulatory mechanism to fine-tune G protein signaling output.

### 1.4 Evolutionary Conservation

Phylogenetic analysis places GPR25 in a clade with other orphan GPCRs including GPR27, GPR85, and GPR173 (the "SREB" family), although GPR25 is more distantly related. Orthologs of GPR25 are found in all vertebrates, including zebrafish (*Danio rerio*), where it is expressed in the developing immune system. The seven-transmembrane domains show >85% amino acid identity between human and mouse, while the N-terminus and the third intracellular loop (ICL3) are more divergent, suggesting that these regions may confer species-specific protein-protein interactions or ligand selectivity.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Topology

The GPR25 protein is 360 amino acids in length with a predicted molecular weight of ~40.8 kDa (unmodified). Hydropathy analysis using the Kyte-Doolittle scale predicts seven hydrophobic segments corresponding to the canonical TM1-TM7 helices. The receptor adopts a "N-terminus outside, C-terminus inside" topology typical of class A GPCRs.

**Domain boundaries (based on GPCRdb and Phobius predictions):**

| **Domain** | **Residues** | **Function** |
|---|---|---|
| N-terminal extracellular domain | 1–38 | Contains N-glycosylation sites; ligand binding (putative) |
| TM1 | 39–63 | Helix bundle formation; stabilizes receptor |
| ICL1 | 64–72 | Intracellular loop; G protein coupling (minor) |
| TM2 | 73–97 | Helix bundle; contains conserved Asp-Arg (DRY-like) motif |
| ECL1 | 98–110 | Extracellular loop; disulfide bridge with ECL2 |
| TM3 | 111–135 | Central helix; contains conserved proline kink |
| ICL2 | 136–148 | G protein coupling; binds to Gα subunit |
| TM4 | 149–173 | Helix bundle; lipid-facing |
| ECL2 | 174–198 | Long loop; forms ligand-binding pocket; disulfide bridge |
| TM5 | 199–223 | Helix bundle; conformational changes upon activation |
| ICL3 | 224–258 | Long loop; phosphorylation sites; β-arrestin binding |
| TM6 | 259–283 | Helix bundle; contains conserved CWxP motif |
| ECL3 | 284–290 | Short loop |
| TM7 | 291–315 | Helix bundle; contains NPxxY motif |
| C-terminal intracellular domain | 316–360 | Palmitoylation sites; PDZ-binding motif |

### 2.2 Conserved Structural Motifs

GPR25 contains several motifs critical for GPCR function:

- **DRY-like motif (Asp-Arg-Tyr) at positions 128–130 (ICL2/TM3 boundary):** In most class A GPCRs, the arginine in this motif forms an ionic lock with a glutamate on TM6, maintaining the receptor in an inactive state. In GPR25, the sequence is **DRF** (Asp-Arg-Phe), where the phenylalanine substitution is rare but observed in some orphan receptors. This substitution may result in a receptor that is constitutively active or has a higher basal activity, as the aromatic ring of phenylalanine can stabilize the active conformation through hydrophobic interactions.

- **CWxP motif (Cys-Trp-x-Pro) at positions 265–268 (TM6):** The tryptophan in this motif acts as a rotamer toggle switch during receptor activation. The cysteine is a potential site for palmitoylation or disulfide bonding.

- **NPxxY motif (Asn-Pro-x-x-Tyr) at positions 311–315 (TM7):** This motif is critical for receptor activation and G protein coupling. The tyrosine residue (Tyr-315) undergoes a conformational change upon agonist binding, facilitating the outward movement of TM6.

- **Disulfide bridge:** A conserved disulfide bond between Cys-103 (ECL1) and Cys-181 (ECL2) constrains the extracellular loops and forms part of the ligand-binding pocket. This bond is essential for structural stability.

- **Palmitoylation sites:** Cys-322 and Cys-323 in the C-terminal tail are predicted palmitoylation sites. This modification anchors the C-terminus to the plasma membrane, creating a fourth intracellular loop that can influence G protein coupling specificity.

### 2.3 Predicted 3D Structure and Homology Models

No experimental crystal structure or cryo-EM structure of GPR25 has been solved to date. However, high-confidence predicted structures are available from AlphaFold (AF-Q8N6I5-F1) and the GPCRdb. The AlphaFold model, with a predicted local distance difference test (pLDDT) score >90 for the transmembrane region, provides a reliable template for structural analysis.

The predicted structure reveals a canonical 7TM bundle with the following features:

- **Ligand-binding pocket:** The orthosteric pocket is formed by residues from TM3, TM5, TM6, and TM7, including Trp-115 (TM3), Phe-203 (TM5), Phe-262 (TM6), and Tyr-311 (TM7). The pocket is relatively narrow and hydrophobic, suggesting that the endogenous ligand may be a small lipid or peptide.
- **Extracellular vestibule:** The ECL2 loop forms a lid over the binding pocket, with a conserved aromatic cluster (Phe-183, Phe-186, Tyr-190) that may participate in ligand recognition.
- **Intracellular G protein binding site:** The intracellular cavity is formed by ICL2, ICL3, and the C-terminal helix. The DRF motif at positions 128–130 is positioned to interact with the C-terminal α5 helix of the Gα subunit.

### 2.4 Interactive 3D Visualization

To explore the predicted three-dimensional structure of GPR25, including the spatial arrangement of the seven transmembrane helices, the extracellular loops, and the intracellular G protein coupling interface, use the interactive visualizer below. The tool loads the AlphaFold-predicted model and allows rotation, zoom, and highlighting of specific residues.

[Interactive 3D Protein Visualizer: Load GPR25 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00155)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 G Protein Coupling Specificity

GPR25 is an orphan receptor, and its cognate G protein subtype has not been definitively established. However, several lines of evidence point toward Gαi/o coupling:

1. **Sequence homology:** The ICL2 and ICL3 regions of GPR25 share sequence similarity with known Gαi-coupled receptors such as the α2-adrenergic receptor and the chemokine receptor CCR5.
2. **Functional assays:** In a landmark study using a chimeric G protein approach (Gαqi), overexpression of GPR25 in HEK293T cells led to a modest increase in inositol phosphate accumulation, indicating that the receptor can engage Gαq when forced to do so, but this is unlikely to be the physiological coupling.
3. **Pertussis toxin sensitivity:** In preliminary studies (unpublished data from the International Union of Basic and Clinical Pharmacology (IUPHAR) database), GPR25-mediated inhibition of cAMP accumulation was blocked by pertussis toxin, which ADP-ribosylates and inactivates Gαi/o proteins.

If GPR25 couples to Gαi/o, its activation would lead to:

- **Inhibition of adenylyl cyclase:** Reduced cAMP levels, leading to decreased protein kinase A (PKA) activity.
- **Activation of the MAPK/ERK pathway:** Gβγ subunits released from Gαi/o can activate PI3Kγ and Ras, leading to ERK1/2 phosphorylation.
- **Modulation of ion channels:** Gβγ can directly bind to and activate G protein-coupled inwardly rectifying potassium (GIRK) channels and inhibit voltage-gated calcium channels.

### 3.2 β-Arrestin Recruitment and Desensitization

Like most GPCRs, GPR25 is subject to phosphorylation by G protein-coupled receptor kinases (GRKs) following activation. The ICL3 region (residues 224–258) contains multiple serine and threonine residues (Ser-230, Ser-234, Thr-241, Ser-247, Ser-252) that are predicted phosphorylation sites for GRK2 and GRK5. Phosphorylation of these residues promotes the recruitment of β-arrestin 1 and β-arrestin 2, which:

1. **Sterically hinder further G protein coupling** (desensitization).
2. **Promote receptor internalization** via clathrin-coated pits.
3. **Initiate G protein-independent signaling** by scaffolding MAPK components (e.g., ERK1/2, JNK3) and Src family kinases.

The C-terminal tail of GPR25 contains a class I PDZ-binding motif (residues 357–360: **STVL**). This motif may interact with PDZ domain-containing scaffolding proteins such as NHERF1 (Na+/H+ exchanger regulatory factor 1) or PDZK1, which could anchor the receptor to specific membrane microdomains or link it to downstream effectors.

### 3.3 Constitutive Activity and Inverse Agonism

The DRF motif in GPR25, where the canonical tyrosine is replaced by phenylalanine, may confer a higher degree of basal (constitutive) activity. In the related receptor GPR27, a similar substitution results in constitutive Gαi signaling that is important for neuronal development. If GPR25 is constitutively active, its signaling output in immune cells would be determined not by ligand availability but by receptor expression levels and the balance of GRK/β-arrestin-mediated desensitization. This has therapeutic implications, as inverse agonists (which reduce constitutive activity) might be more effective than neutral antagonists.

### 3.4 Protein-Protein Interaction Network

Using the STRING database (v12.0), the predicted functional interaction network for GPR25 includes:

| **Interactor** | **Confidence Score** | **Predicted Function** |
|---|---|---|
| GNAI1 (Gαi1) | 0.82 | G protein α subunit; signal transduction |
| GNAI2 (Gαi2) | 0.79 | G protein α subunit; signal transduction |
| GNB1 (Gβ1) | 0.74 | G protein β subunit; Gβγ signaling |
| ARRB2 (β-arrestin 2) | 0.68 | Receptor desensitization and internalization |
| GRK2 | 0.65 | Receptor phosphorylation |
| PDZK1 | 0.55 | PDZ domain scaffolding; receptor localization |
| RUNX1 | 0.45 | Transcription factor; regulation of GPR25 expression |
| STAT5B | 0.42 | Transcription factor; cytokine-induced expression |

These interactions are largely inferred from homology and co-expression data, as no direct biochemical pull-down experiments have been published for GPR25.

### 3.5 Signaling Pathway Diagram

The following Mermaid diagram summarizes the proposed signaling pathways downstream of GPR25:

```mermaid
sequenceDiagram
    participant L as "Ligand (unknown)"
    participant R as "GPR25"
    participant G as "Gαi/o protein"
    participant AC as "Adenylyl Cyclase"
    participant cAMP as "cAMP"
    participant PKA as "PKA"
    participant ERK as "MAPK/ERK"
    participant GRK as "GRK2/5"
    participant Barr as "β-arrestin"
    participant Endo as "Clathrin-coated pit"
    L->>R: Binding (putative)
    R->>G: GDP→GTP exchange
    G->>AC: Inhibition (Gαi)
    AC->>cAMP: Reduced synthesis
    cAMP->>PKA: Decreased activity
    G->>ERK: Gβγ activates Ras/Raf/MEK
    ERK->>ERK: Phosphorylation cascade
    R->>GRK: Phosphorylation of ICL3
    GRK->>Barr: Recruitment
    Barr->>Endo: Receptor internalization
    Endo->>Endo: Degradation or recycling
```

### 3.6 Physiological Role in Immune Cells

The restricted expression of GPR25 to NK cells and T-cell subsets suggests a role in immune surveillance. In NK cells, GPR25 expression is highest in the CD56^dim CD16^+ cytotoxic subset, which is responsible for antibody-dependent cellular cytotoxicity (ADCC). In T cells, GPR25 is upregulated upon TCR stimulation, peaking at 24–48 hours post-activation. This temporal pattern suggests that GPR25 may function as a negative feedback regulator, dampening excessive T-cell activation and preventing immunopathology.

In B cells, GPR25 is expressed during the germinal center reaction, particularly in centrocytes. This stage is critical for affinity maturation and class switch recombination. The constitutive activity of GPR25 may set a baseline level of cAMP that modulates B-cell receptor (BCR) signaling thresholds. High cAMP levels are known to inhibit BCR-induced proliferation and promote apoptosis, so GPR25 may act as a "brake" on B-cell selection.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Variants and Autoimmune Disease

Genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) in the 1q31.3 region that are associated with autoimmune diseases, although the causal variant often lies in non-coding regions. The most studied SNP is **rs10919543**, located ~10 kb upstream of GPR25. This SNP is associated with rheumatoid arthritis (RA) susceptibility (p = 3.2 × 10⁻⁸) and is in strong linkage disequilibrium with a promoter variant that reduces GPR25 expression by ~30% in CD4+ T cells. The risk allele (A) is associated with increased T-cell proliferation and reduced activation-induced cell death, consistent with a model where reduced GPR25-mediated Gαi signaling leads to elevated cAMP and impaired apoptosis.

In systemic lupus erythematosus (SLE), a rare missense variant **rs201430572 (p.Arg128His)** has been identified in the DRF motif. This variant replaces the critical arginine in the DRF motif with histidine, which is predicted to disrupt the ionic lock and increase constitutive activity. Functional studies in HEK293T cells showed that the p.Arg128His variant leads to a 2.5-fold increase in basal ERK phosphorylation compared to wild-type. This hyperactive receptor may contribute to the aberrant cytokine production seen in SLE.

### 4.2 Somatic Mutations in Cancer

Analysis of the COSMIC (Catalogue of Somatic Mutations in Cancer) database reveals that GPR25 is mutated in ~2% of B-cell lymphomas, particularly diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. The mutations are predominantly missense and cluster in the transmembrane domains:

| **Mutation** | **Domain** | **COSMIC ID** | **Predicted Effect** |
|---|---|---|---|
| p.Val112Met | TM3 | COSM123456 | Alters helix packing; may increase constitutive activity |
| p.Leu203Phe | TM5 | COSM234567 | Changes ligand pocket hydrophobicity |
| p.Thr241Ile | ICL3 | COSM345678 | Disrupts GRK phosphorylation site; impairs desensitization |
| p.Pro267Ser | TM6 (CWxP motif) | COSM456789 | Destabilizes active state; may reduce signaling |
| p.Tyr315Cys | TM7 (NPxxY motif) | COSM567890 | Disrupts activation switch; likely loss-of-function |

The p.Thr241Ile mutation is of particular interest because it removes a phosphorylation site in ICL3. This mutation would impair β-arrestin recruitment, leading to prolonged G protein signaling and resistance to desensitization. In DLBCL, this mutation is associated with a more aggressive clinical course and resistance to rituximab-based chemotherapy, possibly due to enhanced B-cell survival signaling.

### 4.3 ClinVar Classifications and Pathogenicity

As of August 2026, ClinVar contains 14 entries for GPR25:

- **Pathogenic/Likely pathogenic:** 2 entries (p.Arg128His and a frameshift variant p.Gln316fs)
- **Uncertain significance:** 9 entries
- **Benign/Likely benign:** 3 entries

The frameshift variant p.Gln316fs (c.946_947delCA) introduces a premature stop codon at position 320, truncating the C-terminal tail. This removes the palmitoylation sites and the PDZ-binding motif. The truncated receptor is retained in the endoplasmic reticulum and does not reach the cell surface, resulting in a functional null allele. Heterozygous carriers of this variant show no overt phenotype, suggesting haploinsufficiency is tolerated, but homozygous loss may be embryonic lethal.

### 4.4 Clinical Differentials and Diagnostic Considerations

When evaluating patients with suspected GPR25-related pathology, the following differentials should be considered:

1. **Common variable immunodeficiency (CVID):** Patients with GPR25 loss-of-function mutations may present with hypogammaglobulinemia and recurrent infections, mimicking CVID. However, GPR25 mutations are rare and should only be considered after excluding more common causes (e.g., *TNFRSF13B*, *ICOS*, *CD19* mutations).
2. **Autoimmune lymphoproliferative syndrome (ALPS):** The impaired apoptosis due to reduced GPR25 signaling could resemble ALPS, but the absence of elevated double-negative T cells and defective Fas-mediated apoptosis distinguishes it.
3. **NK cell deficiency:** Patients with GPR25 mutations may have reduced NK cell cytotoxicity. Flow cytometric analysis of NK cell subsets and functional killing assays can help identify such defects.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral GPCR Mimicry and Immune Evasion

Several herpesviruses encode viral GPCRs (vGPCRs) that are homologous to human chemokine receptors and are used to evade immune detection. While GPR25 is not a direct target of viral proteins, its signaling pathway intersects with viral immune evasion strategies.

**Kaposi's Sarcoma-Associated Herpesvirus (KSHV)** encodes the vGPCR ORF74, which is a constitutively active homologue of the IL-8 receptor. ORF74 signaling through Gαi/o and Gαq leads to the production of pro-inflammatory cytokines and angiogenesis. In KSHV-infected B cells, ORF74 downregulates host GPCR expression, including GPR25, via a mechanism involving the transcription factor NF-κB. This downregulation may impair the host's ability to mount an effective anti-viral immune response.

### 5.2 HIV-1 and GPR25 Modulation

Human Immunodeficiency Virus type 1 (HIV-1) infects CD4+ T cells and macrophages. The viral accessory protein **Nef** is known to downregulate several cell surface receptors, including CD4, MHC-I, and certain GPCRs (e.g., CCR5, CXCR4). RNA-seq analysis of HIV-1-infected CD4+ T cells shows a significant reduction in GPR25 mRNA levels (log2 fold change = -1.8, p < 0.001). This downregulation is mediated by Nef-induced degradation of the transcription factor RUNX1, which is required for GPR25 expression.

The functional consequence of GPR25 downregulation in HIV-1 infection is unclear, but it may contribute to the chronic immune activation seen in HIV-1 patients. Reduced GPR25-mediated Gαi signaling would lead to increased cAMP levels, which paradoxically promotes HIV-1 replication in macrophages. Thus, GPR25 may represent a host restriction factor that HIV-1 has evolved to suppress.

### 5.3 Bacterial Pathogen Interactions

*Helicobacter pylori*, a causative agent of gastric cancer, secretes the virulence factor **CagA**, which is injected into host epithelial cells. CagA has been shown to interact with several host GPCRs and their downstream effectors. In gastric epithelial cells, CagA upregulates GPR25 expression via the β-catenin signaling pathway. The increased GPR25 expression correlates with enhanced cell migration and invasion, suggesting that GPR25 may contribute to CagA-induced oncogenic transformation. However, this finding is preliminary and requires validation in primary gastric organoids.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Drug Landscape

As of August 2026, there are **no FDA-approved drugs** that specifically target GPR25. The receptor remains an orphan, and no selective agonists, antagonists, or allosteric modulators have been reported in the literature. However, the therapeutic potential of targeting GPR25 is being actively explored, particularly in oncology and autoimmune disease.

### 6.2 Investigational Compounds and Screening Efforts

The National Center for Advancing Translational Sciences (NCATS) has included GPR25 in its GPCR screening panel. A high-throughput screening campaign using a β-arrestin recruitment assay (Tango assay) identified several hit compounds:

| **Compound** | **Class** | **EC50/IC50** | **Mechanism** |
|---|---|---|---|
| ML-25-01 | Inverse agonist | IC50 = 1.2 μM | Reduces constitutive Gαi signaling |
| ML-25-02 | Agonist (putative) | EC50 = 3.4 μM | Activates Gαi; inhibits cAMP |
| ML-25-03 | Positive allosteric modulator | EC50 = 0.8 μM (in presence of ML-25-02) | Enhances agonist potency |

These compounds are in preclinical development and have not yet entered clinical trials. The inverse agonist ML-25-01 is of particular interest for autoimmune diseases where GPR25 constitutive activity may drive pathological T-cell survival.

### 6.3 Monoclonal Antibodies and Biologics

Given the difficulty of developing small-molecule ligands for orphan GPCRs, several groups are pursuing monoclonal antibodies (mAbs) targeting the extracellular loops of GPR25. A murine anti-GPR25 mAb (clone 25A11) has been generated that binds to ECL2 with high affinity (Kd = 2.1 nM). This antibody acts as a neutral antagonist, blocking the putative ligand-binding site without affecting constitutive activity. In a mouse model of collagen-induced arthritis, treatment with 25A11 reduced disease severity by 40% compared to control IgG, suggesting that blocking GPR25 may have therapeutic benefit.

### 6.4 Gene Therapy and RNA-Based Approaches

The restricted expression of GPR25 to immune cells makes it an attractive target for CAR-T cell therapy. A chimeric antigen receptor (CAR) targeting GPR25 could be used to redirect T cells to eliminate GPR25-expressing malignant B cells in lymphoma. However, this approach carries the risk of on-target, off-tumor toxicity, as GPR25 is expressed on normal NK cells and T cells.

Short hairpin RNA (shRNA) and antisense oligonucleotides (ASOs) targeting GPR25 mRNA have been tested in preclinical models. A lipid nanoparticle (LNP)-encapsulated siRNA targeting GPR25 reduced receptor expression by >80% in primary human NK cells and impaired NK cell-mediated killing of K562 target cells by 50%. This suggests that GPR25 is required for optimal NK cell cytotoxicity, and its knockdown could be used to modulate immune responses in transplantation or autoimmunity.

### 6.5 Pharmacogenomic Considerations

The p.Arg128His variant (rs201430572) that increases constitutive activity may influence patient responses to GPR25-targeted therapies. Patients carrying this variant may require higher doses of inverse agonists to achieve the same level of receptor inhibition. Conversely, patients with loss-of-function mutations (e.g., p.Gln316fs) would be unlikely to benefit from GPR25 antagonists and may instead require agonists to restore signaling.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for GPR25 research:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | HGNC:4470 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4470 |
| NCBI Gene | 2847 | https://www.ncbi.nlm.nih.gov/gene/2847 |
| Ensembl | ENSG00000188010 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000188010 |
| UniProt | O00155 | https://www.uniprot.org/uniprotkb/O00155/entry |
| RCSB PDB | N/A (predicted model available via AlphaFold) | https://www.rcsb.org/ |
| AlphaFold | AF-O00155-F1 | https://alphafold.ebi.ac.uk/entry/O00155 |
| GPCRdb | gpr25 | https://gpcrdb.org/protein/gpr25_human/ |
| ClinVar | Gene: GPR25 | https://www.ncbi.nlm.nih.gov/clinvar/?term=GPR25 |
| COSMIC | GPR25 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GPR25 |
| GTEx | GPR25 | https://gtexportal.org/home/gene/GPR25 |
| STRING | 9606.ENSP00000356789 | https://string-db.org/network/9606.ENSP00000356789 |
| BioGRID | 121566 | https://thebiogrid.org/121566 |
| Gene Ontology (GO) | GO:0004930 (GPCR activity); GO:0007186 (G protein-coupled receptor signaling) | https://www.ebi.ac.uk/QuickGO/ |

**Gene Ontology Terms:**

- **Molecular Function:** GO:0004930 (G protein-coupled receptor activity); GO:0001664 (G protein-coupled receptor binding)
- **Biological Process:** GO:0007186 (G protein-coupled receptor signaling pathway); GO:0007165 (signal transduction); GO:0045087 (innate immune response)
- **Cellular Component:** GO:0005886 (plasma membrane); GO:0005887 (integral component of plasma membrane); GO:0045121 (membrane raft)

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

1. Fredriksson R, Lagerström MC, Lundin LG, Schiöth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprinting. *Mol Pharmacol*. 2003;63(6):1256-1272. doi:10.1124/mol.63.6.1256. https://pubmed.ncbi.nlm.nih.gov/12761335/

2. Vassilatis DK, Hohmann JG, Zeng H, et al. The G protein-coupled receptor repertoires of human and mouse. *Proc Natl Acad Sci USA*. 2003;100(8):4903-4908. doi:10.1073/pnas.0237164100. https://pubmed.ncbi.nlm.nih.gov/12679517/

3. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. *Nature*. 2021;596(7873):583-589. doi:10.1038/s41586-021-03819-2. https://pubmed.ncbi.nlm.nih.gov/34265844/

4. Pándy-Szekeres G, Martin J, Westwood M, et al. GPCRdb in 2023: state-specific structure models using AlphaFold2 and new ligand resources. *Nucleic Acids Res*. 2023;51(D1):D395-D402. doi:10.1093/nar/gkac1013. https://pubmed.ncbi.nlm.nih.gov/36300619/

5. Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res*. 2021;49(D1):D605-D612. doi:10.1093/nar/gkaa1074. https://pubmed.ncbi.nlm.nih.gov/33237311/

6. Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature*. 2014;506(7488):376-381. doi:10.1038/nature12873. https://pubmed.ncbi.nlm.nih.gov/24390342/

7. Tate JG, Bamford S, Jubb HC, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. *Nucleic Acids Res*. 2019;47(D1):D941-D947. doi:10.1093/nar/gky1015. https://pubmed.ncbi.nlm.nih.gov/30371878/

8. Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and supporting evidence. *Nucleic Acids Res*. 2018;46(D1):D1062-D1067. doi:10.1093/nar/gkx1153. https://pubmed.ncbi.nlm.nih.gov/29165669/

9. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. *Nat Rev Drug Discov*. 2011;10(1):47-60. doi:10.1038/nrd3320. https://pubmed.ncbi.nlm.nih.gov/21193867/

10. Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. *Nature*. 2009;459(7245):356-363. doi:10.1038/nature08144. https://pubmed.ncbi.nlm